C-4REZBiophytis
AI drug discovery, BIO101, longevity therapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-4REZ
C-4REZC-4REZAI drug discovery, BIO101, longevity therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this clinical trial is to learn if BIO101 treatment can improve the muscle strength of participants males and females, aged 18 to 84 years old, suffering from obesity (BMI≥30) or overweight (BMI ≥ 27) with one or more sequelae (e.g., hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, but excluding diabetes), and treated with semaglutide, a GLP1 agonist for 21 weeks. The main questions it aims to answer are: * Is BIO101 administered orally improving muscle strength, as measured with knee extension strength (using isokinetic dynamometry)? * Is BIO101 administration leading to additional medical problems for patients suffering from obesity or overweight with sequelae and treated with semaglutide? After the end of the study (after last patient did the last visit at the clinic), researchers will compare the BIO101-treated arm to the placebo control arm to see if the candidate drug has an effect on muscle strength, physical function, lean body mass and health related quality of life compared to placebo. BIO101 is the candidate drug and placebo is a look-alike substance that does not contain any active drug Participants will be asked to: * Take 2 pills every morning and every evening of BIO101 or placebo orally for 21 weeks. * Simultaneously, take semaglutide for 21 weeks while being on caloric restriction, following the doctor recommendation and approved prescribing information for semaglutide, with dose increasing up to at least a dose level of 1.7 mg and a maximum dose level of 2.4 mg. * Come to investigational site at screening, baseline, week 6, 13, 21 and week 33 (12 weeks after the end of treatment) for checkups and tests. * Answer to phone calls at week 25 and 29 as well (4 and 8 weeks after the end of treatment) on global health status and quality of life.
The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in patients with SARS-CoV-2 pneumonia. Part 1 is a Phase 2 exploratory Proof of Concept (PoC) study to provide preliminary data on the activity, safety and tolerability of BIO101 in the target population. Part 2 is a phase 3 pivotal randomized study to provide further evidence of safety and efficacy of BIO101 after 28 days of double-blind dosing. BIO101 is the investigational new drug that activates the Mas receptor (MasR) through the protective arm of the Renin Angiotensin System (RAS).
The SARA-OBS is a single arm phase 2 clinical trial, with no investigational product and no therapeutic intervention that will be conducted in three European countries, (Belgium, France and Italy), and in the US. 300 community dwelling older adults (men or women≥65 years) reporting loss of physical function and at risk of mobility disability, will undergo mobility functional evaluation and Dual-energy X-ray Absorptiometry DXA scan for body composition determination twice, at six-month interval. Participants aged ≥ 65 years complaining of poor physical function will be selected to perform SPPB (Short Physical Performance Battery)tests. Those with SPPB scores ≤ 8/12 will be selected to perform body composition analysis with DXA Scan. Participants with ALM/BMI \< 0.789 in men and 0.512 in women will be included. The investigational phase will comprise two main visits: the inclusion visit and the 6-month visit. Both the 6-minute walk distance test and the 400-metre walking test will be administered at the main visits. Patient Reported Outcomes (PROs) will be completed by the patients at the same visits.
The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test. The absolute change from baseline in meters/second observed in each treatment group at 6 Month was compared to the placebo group. Due to the Covid pandemic \>50% of data at endpoint was missing, which may have affected the ability of the study to deliver the expected results. Additionally, although the planned duration of treatment was 6 months, it was extended up to 9 months for some participants as a result of the pandemic.
Kreos Capital | BlackRock BlackRock iShares Aladdin Our Company Americas Offshore Asia Australia België Brasil Canada Chile Colombia Denmark Deutschland España Finland France Iceland Italia Magyarország México Nederland Norway Polska Portugal Sweden Switzerland Taiwan - 台灣 United Kingdom United States Österreich Location not listed | EN Home Investment capabilities Investment capabilities Investment strategies Alternatives Equities Multi-asset Systematic investing Enhanced investing Index investing Client services Financial Markets Advisory Securities lending Transition management Our clients … dvice and should not be construed as a solicitation or offering of units of any fund or other security in any jurisdiction. In Latin America , no securities regulator within Latin America has confirmed the accuracy of any information contained herein. The provision of investment management and investment advisory services is a regulated activity in Mexico thus is subject to strict rules. For more information on the Investment Advisory Services offered by BlackRock Mexico plea
Biophytis SA, 6XB3:FRA profile - FT.com Subscribe Sign In Menu Search Financial Times myFT if you don't need to support both core and enhanced --> Search the FT Search Search the FT Search Close Home World US Companies Tech Markets Climate Opinion Lex Stock Picking Game Life & Arts How To Spend It Sign In Subscribe Markets Markets Data Equities Equities Screener Sectors & Industries Company Announcements Director Dealings World Markets Financial Times Close International Edition UK Edition Search the FT Search Top sections Home Show more World link World Middle East war Global Economy … l opportunities. Find Stocks Similar to 6XB3 Go to the Equities Screener Apply Cancel Actions Add to Your Watchlists New watchlist Name Cancel Add Add to Your Portfolio New portfolio Name Currency Select a currency UK Pound (GBP) Argentinian Nuevo Peso (ARS) Australian Dollar (AUD) Bahraini Dinar (BHD) Brunei Dollar (BND) Brazilian Real (BRL) Canadian Dollar (CAD) Chilean Peso (CLP) Chinese Yuan Renminbi (CNY) Czech Koruna (CZK) Danish Krone (DKK) Egyptian Pound (EGP)
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 6 0 obj > endobj 9 0 obj > endobj 10 0 obj > stream x��]I� ��ϯ�s���/� `�5���l(^�F���c�����|��hd�Ԭ"��6���N���w���.��좌1�>�r���(;��3��_J������w�+��w���W�;��_?��co �@���_�9 ���Owo�ѧ��s�:{OZYD�Ǿ��Z��a�A�,��=Y��t�)�K} >ܽy2'�;��%~��f�-Os?u����[!�w���;Z�68K�}��� �?��K���� 8Z�i���S�@w^�|�#��� {Z��z~`�#�LgtЎR J��A�B��Һ�sX� x��C���=��Dx�]��;9kOf�55Ha�������=��hh��O?�حgOzI�d��/Y94�C-�q�-�0�ӫ4��.�_�4Nv1�v�U�4����? [��v1��q����Z�a���6eC�"k��&���&���MR;0\숧���}��ydQ�j�Ql�C���9� j7*#���]N�HB$l\�0��N� ��\=K��xV�u���
SEPTEMBER 27, 2023 Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR SEPTEMBER 27, 2023 Biophytis releases its half-yearly accounts as of 30 June 2023 and provides … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
--> Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million | Corporate - EQS News News Feed Events Feed News + Events Feed Recently viewed news Recently viewed events Show all --> Recently viewed Companies Search Results of news Show all Search Results of Companies Show all Search Results of events Show all Watch list Log in Log in E-mail Address Password Remember Me Log in Forgot Password You have not yet registered? Get your account for free. Register Here Back to log in Forgot Password? We will send you a reset link E-mail Reset Password Ne
APRIL 15, 2024 Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR APRIL 15, 2024 Biophytis files a patent application and strengthens its intellectual property in ob … its intellectual property in obesity Biophytis announces the filing of a patent application in the treatment of obesity, a new indication in which the Company has positioned itself with the announcement of its phase 2 OBA clinical trial. This new patent application, which is expected to be granted as soon as 2025, will strengthen BIO101’s (20-hydroxyecdysone) position in the treatment of obesity in combination with GLP-1 RAs. This new patent will extend the exclusivity … on until 2044. Stanislas Veillet, CEO de Biophytis comments: “This patent application completes Biophytis’ patent portfolio covering its lead drug candidate. This portfolio comprises 14 patent families, including 42 issued patents and 39 patents pending, and covers the main regions of the world, in particular Europe, the United States, Japan and major countries such as Brazil and China. This patent will strengthen our intellectual property in the now key area of o … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study June 30, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“B … ontracts for the manufacturing of registration batches in view of the potential application for Emergency Use Authorization to FDA and/or Conditional Marketing Authorization to EMA The 155 th patient has completed treatment in Part 2 of the COVA Phase 2-3 study and results of second interim analysis are expected in Q3 2021 The full results of the study and the filing for market authorization are now scheduled for Q4 2021 The new timelines have no effect on Biophytis’ strategy … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR JULY 22, 2024 Biophyt … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
Biophytis sets up Asia JV with up to $20M funding | BPTSY SEC Filing - Form 6-K --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto S
Jan 27-29, 90+ Exhibitors at PMWC 2027 Silicon Valley Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to spea … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��YKoGnin �068 ��a�~?���5�6 ~�&8ʁ�H������� ��R�3�[�;c�)4���tu�뫚��ZpY�t�� > .*�Z�P[kE����?���
SGS Partners | Southern Gerontological Society | SGS --> SGS provides the bridge between research and practice, translating and applying knowledge in the field of aging. Menu About SGS About Us Leadership Committees State Ambassadors SGS Partners --> History Past Presidents Policies, Procedures & Bylaws Policy & Advocacy Statement Membership Join SGS / Renew Membership Organizational Members Join SGS --> Events 2026 Annual Conference Upcoming SGS Webinars 2025 Advocacy Forum 2025 Registration Requires SGS Membership to Log In --> 2021 Conference Schedule --> 2025 Call For Abstracts --> … Press --> The Gerontology Student Corner Blog Give To SGS Donate SGS Endowment Fund SGS Scholarship Fund Member Log In Log In Log Out Member Home Conference Registration Member Directory Member Map Member Account Info Member Webinars Southern Gerontologist --> Log In --> Log Out --> SGS Partners Home / Annual Conference / 2019 Meeting Partners SGS 2019 Conference Sponsors The Southern Gerontological Society would like to thank our sponsors for making the 40th Annual Conferen … ment organizations that had identified a gap in the conversion of research into application for the older adult population. Visit Their Website Silver Wellness Partner Master of Health Administration - Appalachian State University The Master of Health Administration online program at Appalachian State University connects busy professionals with the knowledge and skills to lead health care organizations - without having to relocate. Visit Their Website Bronze Plus Sponsors Nat … include innovative coursework, research, and internship experiences, taught by award-winning faculty. Online options are available. Visit Their Website Florida PACE® Providers Association The state of Florida is challenged with providing access to quality healthcare for our aging population. Now, for those who may need nursing home care but who prefer to remain in their own homes, Florida has PACE® - a Program of All-Inclusive Care for the Elderly. Visit Their Website Great … ransportation --> How To Sponsor SGS --> Meeting Archives GRITS Victor Marshall Fellowship SGS Events Calendar --> Student Resources Like us on facebook --> Copyright © 2026 Southern Gerontological Society
Biophytis SA (Form: 6-K, Received: 03/26/2026 13:54:15) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 26, 2026 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 place Jussieu 75005 Paris, France +3
SGS Terrapinn UK World Vaccine Congress Washington Virtual Log in Language Organizing events? Resource center Contact app support Legal Home WVC FULL Agenda Learn more SGS Gold Sponsor Bookmark Products & Services Information SGS is the world’s leading inspection, verification, testing and certification company. With more than 89,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world. The Life Science division serves pharmaceutical, biopharmaceutical, and medical device companies along the entire drug development pathway. With over 40 years’ experienc
Sponsors | Belgian Ageing Muscle Society Skip to main content User account menu Member Area Main navigation Home About BAMS Meetings Publications Links Sponsors Contact Facebook Sponsors Gold sponsor --> Silver sponsor --> --> © Belgian Ageing Muscle Society | All rights reserved Privacy Policy | Cookie Policy Developed by HUMACOM
Past Exhibitors | AGS Annual Meeting Skip to main content Top Secondary Menu Access #AGS26 Register Now Main navigation Menu About Program Schedule Registration Submissions Breadcrumb Home Past Exhibitors 2018 & 2019 Exhibitors A Place for Mom Acadia Pharmaceuticals ACEP Geriatric Emergency Department Accreditation Program Adako USA Adfinitas Health Allied Powers LLC Alzheimer's Association American Board of Internal Medicine American College of Surgeons Geriatric Surgery Verification Program American Occupational Therapy Association American Society of Clinical Oncology - C
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021 June 30, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), today announ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Information on the Annual Financial Statements – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR MAY 30, 2025 Information on the Annual Financial Statem … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 26 0 R 27 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��;ko�H�� �?�ӀD �I2g�����l�E��Y�m"���x|�~��M�%��Y .3��fwUu������� �����m� '�oϒ �^ �~/a��&�7�"��?���f�H�љ�������L�L� *D V�½� �s�� ����!�& �c���֣��mp�O�C�j�Gc _����^ � A���Հ�� ;]���u�P��x0��; e��f��-@{�M�[!�p| ��jl�\o>��D��%0���� av��?�����e�r �w_�;��]s5�1���n�侞�^i.���`�KN`4�&MH2��3 &İPL�bM��c�Iݔ ���j��Y���/�
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
BIOPHYTIS STRATEGIC UPDATE: JOINT VENTURE REGISTRATION FILING SUBMITTED IN HONG KONG – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR BIOPHYTIS S … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
30 Aging Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Aging 30 Employers in 32 locations Employers working on Aging work in 25 other areas Displaying 1 - 15 of 25 related areas Show: 15 50 All Cell and Gene Therapy (6) Therapeutics (5) Regenerative Medicine (4) Artificial Intelligence (3) Diagnostics (3) Alzheimer's (2) Epigeneti
Farmdar Secures Strategic Investment from Asian Development Bank to Scale AI for Agriculture Across Emerging Asia. - Plataforma Media Plataforma Channels Português English 繁體中文 Angola Brazil Cape Verde China Guinea-Bissau Macau Mozambique Portugal Sao Tome and Principe East Timor World Politics Economy Society Culture Opinion Sports Future Partners Lifestyle Plataforma Brands Search Plataforma Channels Português English 繁體中文 Angola Brazil Cape Verde China Guinea-Bissau Macau Mozambique Portugal Sao Tome and Principe East Timor World Politics Economy Society Culture Opinion Sports Future Partne
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��Y[oG i� *� � �;�eO�CH�J.6%U h�Ԋ��� �C_�̮7�wM�P�R�%{g�̹|��˒W�������0� HoJ!}i�ᥳ֕��X�w�_�
Biophytis – Biotech de la longévité & thérapies innovantes (BIO101) Aller au contenu Accueil À propos Plateforme longévité Bio101 BIO101 dans la sarcopénie BIO101 dans l’obésité Biophytis Biopharmaceutical Autres projets Ressources Posters scientifiques et publications Communiqués de presse scientifique Recrutement Investisseurs Cotation en direct Présentation institutionnelle Lettre aux actionnaires Communiqués de presse Assemblées générales Informations réglementées pour l’AMF Dépôts auprès de la SEC Obligations convertibles Bons préfinancés (PFW) Contact pour les investisseurs Contact E … re le communiqué BIOPHYTIS MODIFIE SA LIGNE DE FINANCEMENT AVEC HEXAGON CAPITAL FUND POUR RENDRE RENOUVELABLE SA CAPACITE DE TIRAGE DE 2M€ mai 28, 2026 Biophytis fait un point sur la modification destermes de la ligne de financement par obligations simples mise en place avec Hexagon Capital Fund(« Hexagon ») le 5 août 2025, amendée une première fois le 26 février 2026 et amendée une seconde foisle 22 mai 2026. Ces évolutions s’inscrivent dans la… Lire le communiqué BIOP
Biophytis SA Company Profile - Overview - GlobalData Visit Corporate Site Sign in Search Menu Sign In Who We Are Who We Are Your powerful market insights platform. Book a demo Mission & Values Clients Media People Why GlobalData Resource Center CSR Partners Careers History Investors Industries We Cover Industries We Cover Your curated industry news round-up. Subscribe now Aerospace, Defense & Security Agribusiness Apparel Automotive Banking & Payments Construction Consumer Foodservice Healthcare Insurance Medical Devices Mining Oil & Gas Packaging Pharmaceutical Power Public Se … wanted Did not find what I wanted (Let us Contact you) It's too expensive Other Submit Popular Company Profiles: Abbott Laboratories ; Pfizer Inc ; Medtronic Plc ; Shell plc ; BP Plc ×
%PDF-1.7 �������� 2 0 obj [/ICCBased 3 0 R] endobj 3 0 obj > stream x���wTS��Ͻ7�P����khRH �H�.*1 J��"6DTpDQ��2(���C��"��Q��D�qp�Id�y�͛� �~k����g�}ֺ����LX � �X��ň��g` �l�p��B�F�|،l���� ��*�?������Y"1P������\�8=W�%�Oɘ�4M�0J�"Y�2V�s�,[|��e9�2� �U�(j �MFk�����t,:��.FW��� ���8���c�1�L &���ӎ9�ƌa��X�:� � �r�bl1� {{{;�}�#�tp�8_\ �8��"�Ey�.,�X�����%�%Gщ1�-��9����Ҁ��K��l�.��oo���/�O$�&�'=JvMޞ x��ǥ��{��� �=Vs\�x� ��N柜>�u�����c�Kz=s�/�o�l����|ϝ���?y���� ��^d]��p�s�~��� : ;� ��/;]��7|����W����p�������Q�o�H�!�ɻ��V���sn��Ys}��ҽ����~4��]� =>�=:�`��;cܱ
Pierre J. Dilda - Chief Scientific Officer, IP Director at Biophytis | The Org Platform Enrich Pricing Log in Sign up Biophytis Pierre J. Dilda Unverified Pierre J. Dilda Chief Scientific Officer, IP Director Contact PhD in Pharmacology (Paris V University), Dr. Dilda has more than 20 years of experience in pharmaceutical research, in both academic and industrial settings (Mayoli Spindler Laboratories). Before joining Biophytis in December 2015, he was Senior Research Fellow at the Lowy Cancer Research Center at the University of New South Wales (UNSW) in Sydney, Australia, where he was resp
About Us – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR About Us The Why: Making Humanity's Century-Long, Healthy Lifespan a Reality The world& … ie des Sciences, laureate of the CNRS 2012 médaille de l’innovation [Innovation award] and Officier de l’Ordre National du Mérite, José-Alain Sahel currently runs the Institut de la Vision, a research centre associated with the Hôpital des Quinze-Vingts (Paris), Inserm, and Sorbonne Université (formerly University Pierre et Marie Curie). He is a pioneer in the field of the artificial retina and regenerative treatments for the eye. Several companies have been created as a resu
Biophytis (EPA:ALBPS) | Basculer en Français 10646 Companies 226445 Keywords 154908 Articles 119855 Press releases Search Open main menu Headlines Articles Press releases Search Home Press releases New strategic Milestone for Biophytis: Official Establishment of Its Joint Venture in Asia Basculer en Français Close menu Headlines Articles Press releases REGULATED PRESS RELEASE published on 06/09/2026 at 07:00 from Biophytis (EPA:ALBPS) New strategic Milestone for Biophytis: Official Establishment of Its Joint Venture in Asia Press release New strategic Milestone for Biophytis: Official Establis
How AI’s $391B Market Is Shaping Your Future Search HOME ARCHIVE SIGN IN SUBSCRIBE ALPHA Home Posts How AI’s $391B Market Is Shaping Your Future How AI’s $391B Market Is Shaping Your Future Yves Mulkers Jul 16, 2025 Your browser does not support the audio element. In partnership with Hello {{first_name | AI enthusiast}} AI is reshaping every sector, with 83% of companies now prioritizing artificial intelligence in their business plans and the global market valued at $391 billion. From groundbreaking research to enterprise deployments, today’s trends spotlight the future in motion. Dive in! Lea … h to Build $20M National AI Superco … 🎥 AVer’s TR535N Wins EdTech Breakthrough Award 💊 Biophytis and Lynx Analytics Partner for AI Dru … 🧪 Yale’s AI Retrosynthesis Model Accelerates Chemistry Yale researchers have unveiled a new AI-based retrosynthesis model that dramatically improves the prediction of chemical synthesis routes, promising faster drug development and material discovery. AI is now a catalyst for innovation in chemical research. 🏆 Kempner Institute Wins ICML … 025 Outstanding Paper The Kempner Institute team received the Outstanding Paper Award at ICML 2025 for pioneering masked diffusion models, advancing the state of the art in machine learning and generative AI. Breakthroughs in model architecture are redefining what’s possible in AI. Fact-based news without bias awaits. Make 1440 your choice today. Overwhelmed by biased news? Cut through the clutter and get straight facts with your daily 1440 digest. From politics to sports, jo … the next wave of AI-driven research. 🎥 AVer’s TR535N Wins EdTech Breakthrough Award AVer Information Inc.’s TR535N AI Auto Tracking Camera won the 2025 EdTech Breakthrough Award for video capture innovation, enhancing classroom and remote learning experiences with advanced AI tracking. AI-powered video tools are transforming educational content delivery. 💊 Biophytis and Lynx Analytics Partner for AI Drug Discovery Biophytis has partnered with Lynx Analytics to leverage AI
Biophytis Reinforces Leadership Teams with Three Senior Appointments - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Biophytis Reinforces Leadership Teams with Three Senior Appointments July 8, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Biophytis SA announces the strengthening of its leadership teams with three new appointments of highly experienced healthcare executives. Claude Allary to be me … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BIOPHYTIS SA | Globenewswire Forside Modtag pressemeddelelser Kunder Om Via Ritzau Bliv kunde BIOPHYTIS SA 20.1.2021 08:02:48 CET | Globenewswire | Press release Share Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United States PARIS and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age- … 1 CEST | Press release Mavenir Wins Deutsche Telekom's Partner of the Year Award for Best Network Innovation Investeringsforeningen SDG Invest 26.6.2026 13:01:38 CEST | Pressemeddelelse Opdateret prospekt for Investeringsforeningen SDG Invest Tilray Brands, Inc. 26.6.2026 13:00:00 CEST | Press release Tilray Medical Expands Medical Cannabis Access for Veterans Through Lyphe Clinic at Aldershot’s Armed Forces Weekend Investeringsforeningen BankInvest 26.6.2026 12:56:06 CE
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) Innovation Technology Industry Insights News Events Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) PRESS RELEASE Published September 25, 2023 ACCESSWIRE PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with a … t with Sumitomo Metal Mining and a C$16.9 Million Strategic Investment Upcoming Deadline for Sumo Logic, Inc. (SUMO) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit Live Nation Entertainment, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds LYV Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf Final Deadline Approaching for EOSE Investors: Kessler Topaz Meltzer & … P Reminds Eos Energy Enterprises, Inc. (EOSE) Investors of Class Action Lawsuit Deadline on October 2, 2023 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Generac Holdings Inc. (GNRC) APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit VZ INVESTOR A
"> Brazil Pharma News: Biophytis/Innovation Solutions Partnership; Eurofarma's Major Biotech Investment Search for: Sign in Register Reports Interviews Articles Legal & Regulatory Facts & Figures Op-eds Shop Friday, June 26, 2026 Sign In Register Home Country Reports All Americas Asia-Pacific Europe Middle East & Africa Exclusive interviews All Latest Americas Asia-Pacific Europe Middle East & Africa Articles All Global Latest Legal & Regulatory All The Pharma Legal Handbook Regulatory, Pricing and Reimbursement Marketing, Manufacturing, Packaging and Labeling Preclini … n pharmaceutical company, announced the creation of a corporate venture capital fund aimed at supporting innovative companies in the field of biotechnology. It plans to invest up to USD$100 million in startups, known as biotechs, in the early stages of research and development of medicines. Named Eurofarma Ventures, this corporate fund was established to strengthen the company’s presence in the field of innovation, aiming to collaborate with startups adopting disruptive appro … stment from WE Ventures (Contxto) Radar Fit, the innovative health and wellness application founded in 2018, has announced a USD $1 million investment from WE Ventures, a venture capital (VC) fund that is part of Women Entrepreneurship, an initiative created by Microsoft Participações in partnership with Sebrae Nacional, M8 Partners, and in collaboration with Bertha Capital. This investment, made in conjunction with the recently launched Hiker Ventures, adds up to a total of
Jobs at Biophytis | EuroPharmaJobs Job Search Search for Jobs 0 Saved Jobs Jobs Expiring Soon Search for Jobs My Profile Login Register CV Job Alerts Newsletter Career Guides Saved Jobs ( 0 ) Jobs Expiring Soon Login Register CV Job Alerts Career Guides Conferences Post a Job Recruiter Recruiters Guide Recruiters Recruiters Guide Jobs at Biophytis Biophytis Clear all Search Jobs Jobs By Category Bioinformatics (7) Biotechnology and Genetics (44) Clinical Data Management (3) Clinical Research (70) Data, Programming and Statistics (21) Manufacturing and Logistics (58) Medical (31) Medical
🎥 On the path to a world first, explained by those who made it happen Following the signing of our strategic agreement in Asia, the two leaders behind this milestone share the vision, strategy and… | BIOPHYTIS - Live Healthier Longer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can upd … Biophytis porte à 2 m€ le plafond de sa ligne obligataire avec Hexagon Capital Fund… le titre au plus bas…à 0.049€.. 👏👏 Like Reply 1 Reaction See more comments To view or add a comment, sign in More Relevant Posts LSX Europe 2,685 followers 4mo Report this post 🌍 Europe’s role in global life sciences is being rewritten - by capital, partnerships, and the next wave of innovation. At LSX Europe in Lisbon, we’re bringing strategic leaders together to unpack a bigger que … latform. Contribute to industry transformation and next-generation innovations. Submit your abstract and proposal 👉 https://lnkd.in/gHcjbwC7 Register now 👉 https://lnkd.in/gxAA7YjE Let's shape the next breakthroughs in biotech—together! Unlock the Future of Biotech at BIOHK2026 9 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in ETH Entrepreneurship 28,480 followers 4mo Report this post 🧬 𝗦𝘄𝗶𝘀𝘀 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗗𝗮𝘆 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗕𝗮𝘀𝗲𝗹
🌏 A new chapter is opening for BIOPHYTIS - Live Healthier Longer in Asia. We are proud to announce the official registration of Biophytis Biopharmaceutical Group Limited in Hong Kong, our joint… | BIOPHYTIS - Live Healthier Longer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update … its global pharma reputation on affordable generics - now it's eyeing a bigger prize: Biologics. At the recent Pharma Summit in New Delhi, officials spoke about the 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗦𝗛𝗔𝗞𝗧𝗜 initiative and its goal of 𝟭𝟬𝟬 𝗻𝗲𝘄 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗯𝘆 𝟮𝟬𝟰𝟳, backed by schemes like BIG, SBIRI, BIPP, and the National Biopharma Mission. With biologics set to make up nearly 40% of global prescription drugs by 2031, the stakes are high. What's interesting is the bala
0001768946 --12-31 2023 FY true Biophytis SA I0 Paris FR Sorbonne University-BC 9 75005 false International Financial Reporting Standards 2655000 1911000 17026000 5567000 P30D 584000 100 0.3333 0.3333 0.3333 0.3333 0.3333 0.3333 P3Y 4368000 10211000 1591334 false 0001768946 bpts:AllocationOfBonusSharesApril252021Member bpts:AllocationOfBonusSharesMember 2023-12-31 0001768946 ifrs-full:VehiclesMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001768946 ifrs-full:VehiclesMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001768946 ifrs-full:FixturesAndFittingsMember ifrs-full:Top … eding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes    ☐   No ​ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  … Financial Review and Prospects” of this annual report), will be enough to fund our planned operating expenses into the first quarter of 2025. Accordingly, our current and available capital resources are not sufficient to cover our operating needs for at least the next 12 months. In addition, our current operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds even sooner than planned, through public or priv … ds Issue Agreement with Kreos Capital VI (UK) Ltd. and Kreos Capital VI (Expert Fund) L.P., which provides for up to €10 million in financing to us. Pursuant to the terms of the agreements, Kreos agreed to subscribe for up to €7.75 million in convertible bonds and for up to €2.25 million in non-convertible bonds, to be issued by us in up to four tranches. The first two tranches were issued on November 22, 2021. Each tranche of non-convertible bonds bears a 1 … ds Issue Agreement with Kreos Capital VI (UK) Ltd. and Kreos Capital VI (Expert Fund) L.P., and our convertible notes agreements with ATLAS impose certain operating and financial restrictions. These covenants may limit our ability and the ability of our subsidiaries, under certain circumstances, to, among other things: ● incur additional in
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> Biophytis (NASDAQ:BPTS) Share Price | RNS News, Quotes, & Charts | BPTS | @ element('Front/sign_in_out_buttons') --> USA UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news Live Market reports OTC Markets Small caps Eli Lilly shares rise after EU panel backs expanded use of Jaypirca 10:56 26 Jun --> SpaceX reportedly plans Starlink mobile service for US consumers 10:27 26 Jun --> Onsemi shares slide on $7B Synaptics deal 10:05 26 Jun --> Nasdaq takes another hi
%PDF-1.6 %���� 439 0 obj > endobj 465 0 obj >/Filter/FlateDecode/ID[ ]/Index[439 45]/Info 438 0 R/Length 125/Prev 1706513/Root 440 0 R/Size 484/Type/XRef/W[1 3 1]>>stream h�bbd```b``i� � �QD����]��'0y D���H�z0� D����ը�H%�4,r n��U�?H��1��֊ � ��1��| f_��Z~00120�����HC�?c���&w endstream endobj startxref 0 %%EOF 483 0 obj >stream h�b```f``�a`�Q � �����������X����G�c�fv���s��"S��4+��`��R���ԧk�h��м��ˮ�;� �:|Ta���tC�Q��g��g�SUߘp5�T��$"ء�&W8mvI������j>:J3���l�,{D�8'.~�f�ʒ#Y�v��s^����D!�C��VE�/�Q�˚5M��Mi �L�zi@&3=�t�f�P;tk��w�fko]�NDpC�O�� jY� �\Yr8T�mPJ … :fc0ff720-db70-11fa-0000-d4729d2aa4aa uuid:2a32034f-fb69-4e85-b527-05204691505c application/pdf Untitled endstream endobj 256 0 obj >stream h�4�1 �0�� ��.&���� A���+��ف��c�*SE����.eI��t���ӭ��>%������\h���sx�0�B ~b������I t� �n�e>��` �+� endstream endobj 257 0 obj >stream h�D�� �0%[�潴���X��A��,IH#��U�����3`m+O�N��O����@ՈHX) ������Ç�?Ƹ8�-����H!4h�(� S0Om �3��U'3kJ�������?4��� Q�-� endstream endobj 258 0 obj >/Filter/FlateDecode/ID[ ]/Info 438
EX-10.22 24 a2242774zex-10_22.htm EX-10.22 Exhibit 10.22 PORTIONS OF THIS EXHIBIT IDENTIFIED BY [*****] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COLLABORATION AGREEMENT Between BIOPHYTIS , a French public limited company with a Board of Directors and a share capital of 2,692,682 euro, having its registered office at 14 avenue de l’Opéra, 75001 Paris, registered with the Paris Trade and Companies Register under number B 492 002 225, represent … mercial, scientific, financial, etc.), nature (invention, patent or patent application, declaration of invention, discovery, technical, know-how, methods, processes, technical records, drawing, specification, algorithm, etc.), medium (written or printed documents, CD-ROM, USB stick, samples, material, drawings, etc.), 1st method of transmission (written, verbal, electronic or digital, etc.) and form (tangible or intangible), marked as confidential or not. … ;   Any late payment of the sums due hereunder shall give rise to the application by IDF Innov of a penalty equal to three (3) times the legal interest rate, payable from the day after the due date of the receivable. In addition to the late payment compensation, BIOPHYTIS shall be liable for a fixed-rate compensation of [****] euro towards the recovery costs of any amount not paid on its due date. Article 5 - Intellectual Property 5.1.   … hether all or part of the Results must be the subject of the filing of a patent application or any other means of protection. 5.2.1              In the event that the Results would make it possible to file a patent application or any other intellectual property title, the Parties agree to file said patent application or title in the joint names of UPDescartes and BIOPHYTIS and to establish co-ownership regulat … ions), national/regional phases, examination, acquisition, issuance of a patent application or corresponding patent in one or more countries, it shall inform the other Party thereof by registered letter with A/R as soon as possible before the next expiry of Industrial Property and before instruction to the firm, that is, upon receipt of a new act
JUNE 12, 2024 – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR JUNE 12, 2024 Biophytis announces the successful industrial transfer of BIO101 (20 … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer September 14, 2023 | 4 min read Twitter LinkedIn Facebook Email Print Biophytis SA today announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Offi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Appointment of Edouard Bieth as Chief Business Officer Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR SEPTEMBER 14, 2023 Biophytis Strengthens its Management Tea … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
SEPTEMBER 3, 2025 – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR SEPTEMBER 3, 2025 Biophytis obtains EMA authorization to launch its Phase 2 cl … nes Agency (EMA) has issued a favorable outcome on Part I of its Clinical Trial Application (CTA) for the initiation of a Phase 2 clinical trial of BIO101 (20-hydroxyecdysone) in patients suffering from muscle wasting associated with obesity (OBA study). This milestone represents a crucial regulatory step in advancing Biophytis’ clinical development strategy within Europe. The favorable review of the scientific dossier (Part I) confirms the quality, safety, and preclinical/cl … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/ebook -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=100 -dGrayImageResolution=100 -dMonoImageResolution=100 -dNOPAUSE -dQUIET -dBATCH ? ? ? 6 0 obj > stream x���v�Gr&�:��'�՜�H�AQ~��zC��U��E"����f R��d�_������������D�YE��*� �}�nnnn��?l�Vn���^���a�
Biophytis Reinforces Leadership Teams with Three Senior --> Accessibility: Skip TopNav Biophytis Reinforces Leadership Teams with Three Senior Appointments July 08, 2021 02:00 ET | Source: BIOPHYTIS SA BIOPHYTIS SA Claude Allary to be member of Board of Directors Benoit Canolle is appointed Chief Business Officer Jean Mariani, Chairman of Biophytis Scientific Committee to take over the Chief Medical Officer role PARIS and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biot
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/ebook -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=100 -dGrayImageResolution=100 -dMonoImageResolution=100 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x�u�1�0 �ݧ�'vM�t�e�tj���K�:��d[_op{>;�t��J�d`Hb��F���ㆭ� ���S��S��_]z�6iP�[Fk���q�ivkҞ���0
EX-10.5 7 a2242774zex-10_5.htm EX-10.5 Exhibit 10.5 PORTIONS OF THIS EXHIBIT IDENTIFIED BY [*****] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Ref. UPMC: Ref. SATTLUTECH: LIC3-2015-0011 (ST00022) Linked file: BIOPHYTIS_Sarcob Translation for information purposes only LICENSE AGREEMENT This agreement is concluded between: ·               … 0;          OUT OF SCOPE means any application other than the one defined by the SCOPE. 1.13            PATENTS collectively means: ·                  The patents and patent applications listed in appendix 1 hereto to form an integral part thereof; ·      … cations, renewals, claiming all or part of the priority of the patent or patent application listed above. 1.14            PRODUCTS collectively means NUTRACEUTICAL PRODUCTS and MEDICINAL PRODUCTS. 1.15            SCOPE means any application related to obesity (including sarcopenic obesity), sarcopenia, diabetes, muscular dystrophies including genetic ones (includi … 60;      By this LICENSE AGREEMENT, the ESTABLISHMENTS grant to BIOPHYTIS the exclusive right to exploit the quota held by the ESTABLISHMENTS on the PATENTS, within the SCOPE and the TERRITORY. This exclusive right is granted in order to allow BIOPHYTIS, directly or indirectly, in an exclusive context, to develop, use, manufacture, market, sell, import or export and distribute the PRODUCTS. 5 BIOPHYTIS may exercise its rights and perform …    The rights granted to BIOPHYTIS pursuant to article 2.1 above also grant BIOPHYTIS the right to grant to 6 THIRD PARTIES licences to the PATENTS within the SCOPE and the TERRITORY under the conditions detailed in this article. Within the limits of the provisions of the LICENSE AGREEMENT, BIOPHTYIS may grant to a
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.2 841.8] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��SKK�@�� �����G6 "�aKE�G�C�k{h�u=��M+�&bX�d���, n�z�/=������x� ��כ'�}��6/�U��u� >�}(M��ۋ M�0��OP��U !z,��X* d�8P��ك��#|��hу�dWqtI > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > stream ����JFIF����C $.' ",# (7),01444 '9=82 ��Y� U� ԊЭ���Rj�R� A(
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/ebook -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=100 -dGrayImageResolution=100 -dMonoImageResolution=100 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��]I�Ǖ�/� ��mQS����$J��! i�^��� x��n� � � |��� 0'���y/חU �S�}P�*�����-��Ӵmش�����n �˗zzu��
JULY 30, 2025 – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR JULY 30, 2025 Biophytis Joins Silver Innov’, an Incubator Dedicated to the S … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
NOVEMBER 27, 2023 – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR NOVEMBER 27, 2023 Biophytis appoints Yann Meunier and Bernard Lévy to its Scie … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
Biophytis – Biotech de la longévité & thérapies innovantes (BIO101) Aller au contenu Accueil À propos Plateforme longévité Bio101 BIO101 dans la sarcopénie BIO101 dans l’obésité Biophytis Biopharmaceutical Autres projets Ressources Posters scientifiques et publications Communiqués de presse scientifique Recrutement Investisseurs Cotation en direct Présentation institutionnelle Lettre aux actionnaires Communiqués de presse Assemblées générales Informations réglementées pour l’AMF Dépôts auprès de la SEC Obligations convertibles Bons préfinancés (PFW) Contact pour les investisseurs Contact E … re le communiqué BIOPHYTIS MODIFIE SA LIGNE DE FINANCEMENT AVEC HEXAGON CAPITAL FUND POUR RENDRE RENOUVELABLE SA CAPACITE DE TIRAGE DE 2M€ mai 28, 2026 Biophytis fait un point sur la modification destermes de la ligne de financement par obligations simples mise en place avec Hexagon Capital Fund(« Hexagon ») le 5 août 2025, amendée une première fois le 26 février 2026 et amendée une seconde foisle 22 mai 2026. Ces évolutions s’inscrivent dans la… Lire le communiqué BIOP
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 6 0 obj > endobj 9 0 obj > endobj 10 0 obj > stream x��]I� �����8���y. ���,$y�2�� #�� �,��W���m�co���$��(���N�8�����.��ꢍ�]��t��;�D��*\�?����-��1���?����.�T�lP�����W�!�C^�����2��Ͽܽ�Q_�������������� ������O}���.R����N ��^��D�Y � r����ݻ__~��ݯ ~��>{�����ݻGB^wZ���g�x���$ͩ�移 ������_�|������ /7f��.JgBp�; �)��/��&�n�"Lgt�A�jK� �Ѕ(b���J��s��oʎ�~���ݧ�e�!9�%g�Q��$V�K �RQ̠ �%(�Kk!ڄ�%�}�]���SCjyǗ��?�����G����gy��KSgy��v�>�����_c=|vս���P��� =� �t���t槗Ty"�e"[4�uP �)�$M3y���9E�6�Q����$�2x�����Q=�4-�����4|���wQHg�:����v�K'�
Biophytis to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3 | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Forum Bourse BIOPHYTIS - 02/11/2022 11:49:29 - News 2 - Boursorama Aller au contenu principal Contraste renforcé Rafraîchissement automatique Bourse Fermer Message d'erreur Menu BIOPHYTIS 0,02 0,00% Rechercher Aide Espace Membre Espace Client Connexion Sur quel site souhaitez-vous vous connecter ? Accès Espace Client BoursoBank Espace Membre Boursorama.com Chargement... Menu Rechercher Aide Espace Membre Espace Client Connexion Sur quel site souhaitez-vous vous connecter ? Accès Espace Client BoursoBank Espace Membre Boursorama.com Chargement... Bourse Actualités Actualités Points de marchés A
F-3 1 tm2313194d1_f3.htm F-3 As filed with the Securities and Exchange Commission on April 21, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biophytis S.A. (Exact name of Registrant as specified in its charter) France Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number)   … as the case may be, the Deputy CEO. 9 Directors' Voting Powers on Proposal, Arrangement or Contract in which any Director Is Materially Interested (Article 21 of the Articles of Association). Except for those relating to current operations concluded under normal conditions, any agreement entered into, directly or indirectly through an intermediary, between the Company and any of our directors, CEO, deputy CEOs or with a shareholder holding more than 1 … allocate 5% of our unconsolidated net profit for each year to our legal reserve fund before dividends may be paid with respect to that year. Funds must be allocated until the amount in the legal reserve is equal to 10% of the aggregate par value of the issued and outstanding share capital. This restriction on the payment of dividends also applies to our French subsidiary on an unconsolidated basis. Approval of Dividends. Pursuant to French law, … and we may not exercise the preemptive rights attached to them. Sinking Fund Provisions. Our articles of association do not provide for any sinking fund provisions. Liability to Further Capital Calls. Shareholders are liable for corporate liabilities only up to the par value of the shares they hold; they are not liable to further capital calls. Requirements for Holdings Exceeding Certain Percentages. … articipating shareholder; · our shareholders have granted and may grant in the future our board of directors broad authorizations to increase our share capital or to issue additional ordinary shares or other securities, such as warrants, to our shareholders, the public or qualified investors, including as a possible defense followin
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��Y_oE_��܊&j�����!m���������д���`C�x( TD� �B + ��$�~�+����O�~����@�K+�w�� � �� �0�� Cb�2$
Biophytis Insights - Episode 1 | BIOPHYTIS - Live Healthier Longer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Pr
Public funding in Brazil for Obesity Phase 2 Trial Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR SEPTEMBER 15, 2025 Biophytis Secures public funding in Brazil f … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
Second episode of our exclusive series featuring Stanislas Veillet, CEO of Biophytis | BIOPHYTIS - Live Healthier Longer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o
Posters scientifiques et publications – Biophytis Aller au contenu Accueil À propos Plateforme longévité Bio101 BIO101 dans la sarcopénie BIO101 dans l’obésité Biophytis Biopharmaceutical Autres projets Ressources Posters scientifiques et publications Communiqués de presse scientifique Recrutement Investisseurs Cotation en direct Présentation institutionnelle Lettre aux actionnaires Communiqués de presse Assemblées générales Informations réglementées pour l’AMF Dépôts auprès de la SEC Obligations convertibles Bons préfinancés (PFW) Contact pour les investisseurs Contact EN FR EN FR Poste
À propos – Biophytis Aller au contenu Accueil À propos Plateforme longévité Bio101 BIO101 dans la sarcopénie BIO101 dans l’obésité Biophytis Biopharmaceutical Autres projets Ressources Posters scientifiques et publications Communiqués de presse scientifique Recrutement Investisseurs Cotation en direct Présentation institutionnelle Lettre aux actionnaires Communiqués de presse Assemblées générales Informations réglementées pour l’AMF Dépôts auprès de la SEC Obligations convertibles Bons préfinancés (PFW) Contact pour les investisseurs Contact EN FR EN FR À propos Notre raison d’être : fai
Strategic agreement signed in Asia — a decisive step for BIO101 in sarcopenia 🖋️ From vision to execution, after announcing a Memorandum of Understanding, BIOPHYTIS - Live Healthier Longer is… | BIOPHYTIS - Live Healthier Longer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update y
%PDF-1.4 %���� %ABCpdf 11303 1082 0 obj > endobj xref 1082 34 0000000032 00000 n 0000001635 00000 n 0000001780 00000 n 0000002755 00000 n 0000002983 00000 n 0000003030 00000 n 0000003193 00000 n 0000004237 00000 n 0000004498 00000 n 0000004944 00000 n 0000005112 00000 n 0000006053 00000 n 0000006314 00000 n 0000006729 00000 n 0000007891 00000 n 0000008206 00000 n 0000008312 00000 n 0000008477 00000 n 0000008636 00000 n 0000008879 00000 n 0000009049 00000 n 0000009946 00000 n 0000010217 00000 n 0000010647 00000 n 0000010806 00000 n 0000011069 00000 n 0000011326 00000 n 0000011643 00000 n 000001
Biophytis Appoints Professor Thomas Voit to Scientific Advisory Board to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Biophytis Appoints Professor Thomas Voit to Scientific Advisory Board to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases October 27, 2017 | 6 min read Twitter LinkedIn Facebook Email Print Professor Voit is the Director of the Biomedical Research Centre of the Great Ormond Stre … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BIOPHYTIS and a Consortium of Investors including Join Forces Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR OCTOBER 13, 2025 BIOPHYTIS and a Consortium of Inves … investors is expected to invest up to US$20 million over the next two years to fund the Phase 3 clinical trial in sarcopenia. It is also anticipated that Biophytis will eithertransfer ownership or grant an exclusive license to the joint venture for certain patents related toBIO101, registered or to be registered in China, Korea, and Japan. This study is expected to include up to 932 patients in Europe and Asia, including China and Japan. Its completion would bring hope for t … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
%PDF-1.4 %���� 1122 0 obj > endobj xref 1122 30 0000000016 00000 n 0000002441 00000 n 0000002585 00000 n 0000002608 00000 n 0000002834 00000 n 0000002986 00000 n 0000003024 00000 n 0000064854 00000 n 0000065096 00000 n 0000066092 00000 n 0000066519 00000 n 0000066665 00000 n 0000092541 00000 n 0000092773 00000 n 0000093179 00000 n 0000093566 00000 n 0000093707 00000 n 0000128285 00000 n 0000128512 00000 n 0000129000 00000 n 0000129397 00000 n 0000129533 00000 n 0000176324 00000 n 0000176566 00000 n 0000177452 00000 n 0000177850 00000 n 0000178001 00000 n 0000178026 00000 n 0000178097 00000 n 0 … d. 2021-03-17T09:53:06+01:00 2021-03-17T09:53:06+01:00 Aspose.PDF for .NET 19.9 application/pdf uuid:29e941f5-de24-42b3-994e-32869663103f uuid:13f5eefa-c148-47d5-8fe7-893da6f27768 endstream endobj 1121 0 obj > endobj xref 0 1122 0000000000 65535 f 0000181959 00000 n 0000182126 00000 n 0000182276 00000 n 0000182298 00000 n 0000182449 00000 n 0000182594 00000 n 0000182823 00000 n 0000182914 00000 n 0000183215 00000 n 0000184189 00000 n 0000189252 00000 n 0000189422 00000 n 0000
Infectious Disease R&D Partnerships, M&A, Ventures, and IPO Activity – 2024 Review - DealForma Skip to content Features Pricing Blog DealForma Research Media Coverage Sign in Features Pricing Blog DealForma Research Media Coverage Sign in Sign In Schedule a demo Infectious Disease R&D Partnerships, M&A, Ventures, and IPO Activity – 2024 Review By Ani Harutyunyan Jan 7, 2025 Analysis , Funding , M&A , Partnership Deals Our 2024 review of infectious diseases highlights impactful financial activity across R&D partnerships, mergers and acquisitions, venture funding, and I … e fungal infections, announced a $100 million financing round led by AMR Action Fund and ICG, with support from investors like Novo Holdings, Advent Life Sciences, and Sofinnova Partners. The funds will advance the late-stage development and U.S. commercialization of olorofim, an oral antifungal therapy for invasive aspergillosis and other invasive fungal infections. The financing will close in Q4 2024, pending the clearance of Austria’s Foreign Direct Investment.  
Biophytis enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR Bio … terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first… Read more March 26, 2026 Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC,… Read more March 13, 2026 Biophytis SA announces that it participated in the Intrinsic Capacity, Fra
%PDF-1.7 4 0 obj (Identity) endobj 5 0 obj (Adobe) endobj 8 0 obj > stream x��} `T����o��f{���%��� �C6vd��A��"���n5~V���*.�b[k�V�Ԁ��j��Rm���VQ�����V[���}o&�JI�o��~�{�˻���=w�>$ �4y��i����j* vL� b��^y��;k_�-��K��w��U�W�q������Wc���s �_�p��7]xӃ�^��^��q֪s�a�˼ �iX_f��u+���w���m1�*�^~�z����x�'x|��U�����˱=^��{��Wힸr�+w�O]�n�L)l��h���Z�����L� �0�˹6{�Ź���ҁe�Dw5�c �S��� \���L��M��ӱ��0��+����� �VtQtc��|��5S�^��u:ĩ�Z g���e���\ݲ�L��A�H}������=p�ʿw�8����& )g%�A7�:5|���>r�y7f>�#��4�/]�� ~ Y�߈y� ˹(�]9�����G��?���� �w��Y0B�ee���c����&�:�%�?����?�N��t��� �?� ���㧮:t��� … �}�t2\J7ՏZ������Q\���-刚[� "���Xo�f��{�R�է�)=.]�N�/b�)a ��}�i7l]�{ �5�9�S�RFP@�}kj���i�8����%�F���$�E��E_��YD,�c��SM�&���nf`�ǹ��7M��)u~��JP�t���} � ��]fX䙙x'���W)���vo��f�x��Kx��i�����o4����c�0o���LԵǵ�����7;s����o _=ͳ�+nh��Tʝ��Ե�6���Ȱ��(��(��(��(��vY!���r��ȭ�� ��$���|H�lbY��y�˕�:Զ����ެ7ĺ��/Oj�K�f��%��A�N)y���#�Q�8�Z��%c+���� ���D�Hɸ��[�kw��t�XdsV�R6�£��Y�:�v��Vې1^���5+�=DZ^1pNz�+å�$lU�����.kb]H2�xt=��װty��3^� ^���u�2���Bۏ����[:���+��X�Z 7�ҍ … �j��_.�6���Z�^$�6�F�֣� �s�9��udI��'�V��W$#��8�gE�b�t> �tm����P�~�(8����rFp sR��/�$ ��*v�?�a�CWY�?�f9��"7 d�z�t3 '���U^衹�\�G{:��v:�ż�ս=�]^//Sv�Nj�a[p����N�:�IU��gRp���Q�pws�Z��7NV ��{D�: �0�M ���ϗx�� i�д�������bB�$ �WG*��0��n^}���L#��.�>p}����=�F�-ڹ�,�cv +_D���Q��������N3�2?$��j+7�A'# �"�i�x#�\��"^2NW����EKk��#���F���`jp���@�^����w+��M� ����t|3� ����; �V�M ���7�68�T��~a�֣�m ��D\��j̸�,jOg �y�0W#9 �J�R� 7�E�� �K�:�Kwb/m�؛�Q�Zq�+�����l[
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��YKo Enin����ÉI�9$�cw��=� �y8���.ĈC H� ��� ��{f��w�q��8D+�NOWU�����n§�}�nt>���� ����1�Y;�~��\
Biophytis Biopharmaceutical – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR BIOPHYTIS BIOPHARMACEUTICAL (HONG KONG) GROUP LIMITED Accelerating A … ARA-31 Obtain conditional Marketing Authorization (MA) for BIO101 in sarcopenia Submit Marketing Authorization applications in Asia and Europe Validate the efficacy and safety of BIO101 in an international population of patients with sarcopenia This study represents a crucial step toward broadening access to this innovative treatment for older adults suffering from progressive muscle loss. Our Partner: Ronghui Renhe Group Ronghui Renhe Group is a healthcare conglomerate headq
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/ebook -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=100 -dGrayImageResolution=100 -dMonoImageResolution=100 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��Z�r����_1�LD3��߸\j-G+�En%�*U����,�(��� kw1f��h314Ӭ�a.z3�H �4�C3�]�Aǻ4�6��wi>C3�]���4+z� … �B�:?���Я>���^A�����E;b�Ώ�z'��(�����} ��Q�>�� �o��R��Ώ�z'��)UѾ�)���T֓=��rFp���ښ���]��6�v("��)JZ�=a�QE! ���P�� ��U��� ���/��1N����/�������54SE2�Du�VW�V��%x�4E?,�� ��J�b ��F��9���7S�J�(���=Q(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��*����e$A��X��,���*�z�LRWMQY��uH呖H��f,A� ��P}�_���;����f7g��~�� �1��� �H��/٢ݻ`�͙�gң����}QEA�f 4�V�69'vN: �sO�粆Y>�'���{+y�6.B@Gz� qMB/P��)h���P��(��(��(�z
%PDF-1.3 %��������� 3 0 obj > stream x��{��Ʊ��秠wf����,k-�:��IJ6�I�؉�k�� �>����{�W����U"�� �@uuu����o�o���}��ߊ�w� ���}�W�Cy�k��9 �n��۟؞����-}���t�|�a��Çr[l?�e��������~���Ѳ�� ���-�S�P���m�� ���N�i�é�*pk��.�?V��=u�28���?A�9�Ǻ߀���NU� �N/�,�� X�D���é*����kl"��^]]�r��_�߯�nn��v��~����~��+������o�_!�������)�7�>����ް�c֙��eѝ=����mO�������NG��,��Ө���֤jxPy�8��7�T��{,kXxq���B� ��v��P��b�ö�&���wߏߵmq(�c��~|6|��~�O��m�Y~9m��B ������_��?��͟��ݟ����?~����R�S��)��_Vd���/(�_� �u� � �����U� �`��q!V��u����|��>��3����M� ��O��x��������t{�}Կ�����i07����G}����g����{��g
SEC Filings – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR SEC Filings June 16, 2026 Form: 6-K Open the document June 9, 2026 Form: 6-K Open th … n June 10, 2024, Biophytis S.A. issued a press release announcing filing of IND application with the US FDA for its phase 2 study in obesity. Open the document June 7, 2024 Form: 6-K On June 7, 2024, Biophytis S.A. issued a press release announcing that it will hold a Combined General Meeting (CGM) on June 24, 2024. Open the document May 14, 2024 Form: 6-K On May 14, 2024, Biophytis S.A. issued a press release announcing the design of its phase 2 OBA clinical study in obesity … , 2024, Biophytis S.A. issued a press release announcing the filing of a patent application and that the company strengthens its intellectual property in obesity. Open the document April 9, 2024 Form: 6-K On April 8, 2024, Biophytis S.A. issued a press release announcing its 2023 financial results and provides an update on its business activities. Open the document April 9, 2024 Form: 6-K On April 8, 2024, Biophytis S.A. issued a press release announcing that it launches OBA … at the company has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (Ruvembri). Open the document May 25, 2023 Form: 6-K On May 25, 2023, Biophytis S.A. issued a press release announcing its presentation of positive results of Phase 2-3 COVA study at the American Thoracic Society International Conference. Open the document May 15, 2023 Form: 6-K On May 15, 2023, Biophytis S.A. issued a press release an
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��=is �r��+��.w�� ��%�4W�H� ���%��Jů�����4���8~U�\e��F��h����I]�I���������=����n ���h#��7
Buy Biophytis S.A Stock – BPTS Stock Quote Today & Investment Insights - Public.com Skip to main Stocks Options ETFs Crypto Bonds High-Yield Cash Account API Agents More About Us Learn Support Sign In Get Started Biophytis S.A BPTS is now BPTSY This stock has changed its ticker name. This happens for a variety of reason, including a corporate merger or simply a change in company name. Learn More Go to the new stock page Biophytis S.A Stock News View all Biophytis Announces Transfer of ADSs to OTC Market Accesswire • 04/24/24 Biophytis Announces Ratio Change Under its American Depositary Re … r iOS or Android. 2 Add funds to your Public account There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer. 3 Choose how much you'd like to invest in BPTS stock Navigate to the Explore page. Then, type BPTS into the search bar. When you see BPTS stock appear in the results, tap it to open up the purchase screen. 4 Manage your investments in one place You can find your newly purchased BPTS st … during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Public’s Investing’s Fee Schedule to learn more. Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more. Investment Plans. Investment Plans (“Plans”) shown in our marketplace are for i
🚀 Exciting News: Pioneering Partnership to Launch First-Ever Phase 3 Sarcopenia Trial! | BIOPHYTIS - Live Healthier Longer LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi … rst cohort - giving Australian infectious disease innovators the opportunity to apply for non-dilutive funding and expert support. Biointelect Venturer - Australia’s national incubator for vaccine and infectious disease innovation - is supported by the Australian Government Department of Health, Disability and Ageing 's Medical Research Future Fund ( #MRFF ) under the 2024 BioMedTech Incubator Grant Opportunity. Over the next four years (2026–2029), the incubator will guide t … rst cohort - giving Australian infectious disease innovators the opportunity to apply for non-dilutive funding and expert support. Biointelect Venturer - Australia’s national incubator for vaccine and infectious disease innovation - is supported by the Australian Government Department of Health, Disability and Ageing 's Medical Research Future Fund ( #MRFF ) under the 2024 BioMedTech Incubator Grant Opportunity. Over the next four years (2026–2029), the incubator will guide t … rst cohort - giving Australian infectious disease innovators the opportunity to apply for non-dilutive funding and expert support. Biointelect Venturer - Australia’s national incubator for vaccine and infectious disease innovation - is supported by the Australian Government Department of Health, Disability and Ageing 's Medical Research Future Fund ( #MRFF ) under the 2024 BioMedTech Incubator Grant Opportunity. Over the next four years (2026–2029), the incubator will guide t
%PDF-1.4 %���� %ABCpdf 11303 1109 0 obj > endobj xref 1109 34 0000000032 00000 n 0000001635 00000 n 0000001780 00000 n 0000002798 00000 n 0000003026 00000 n 0000003073 00000 n 0000003236 00000 n 0000004310 00000 n 0000004571 00000 n 0000005033 00000 n 0000005201 00000 n 0000006142 00000 n 0000006403 00000 n 0000006808 00000 n 0000007970 00000 n 0000008285 00000 n 0000008391 00000 n 0000008556 00000 n 0000008715 00000 n 0000008958 00000 n 0000009128 00000 n 0000010023 00000 n 0000010294 00000 n 0000010727 00000 n 0000010886 00000 n 0000011149 00000 n 0000011406 00000 n 0000011723 00000 n 000001
Biophytis SA Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Sign In Free Trial Sign In Free Trial Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Biophytis SA https://www.biophytis.com/en/ Industry Pharmaceuticals Vaccines Biotechnology Drug Discovery Technologies Molecular Diversity Natural Products See more in Biomedtracker Latest on Biophytis SA Already A Biomedtracker Subscriber? You have access to the full company record through your subscription. Go To Biomedtracker Twitter feed RSS feed RSS feed Podcast Spotify About About Us Opens in new w … st Spotify About About Us Opens in new window Meet the Team Editorial Standards Award-Winning Journalism Help Advertise Opens in new window Contact Us Evaluate Home Account My Account My View Email Preferences Start Free Trial Opens in new window Publications Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Terms and Conditions Opens in new window Privacy Policy Opens in new window
[6-K] Biophytis SA Current Report (Foreign Issuer) | BPTSY SEC Filing - Form 6-K --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto
Home – Biophytis Skip to content Home About Us Longevity Platform Bio101 BIO101 in Sarcopenia BIO101 in Obesity Biophytis Biopharmaceutical Other Projects Resources Posters & Publications Scientific Press Releases Recruitment Investors Stock Information Corporate Presentation Letter to shareholders Press Releases General Meetings AMF Regulated Information SEC Filings Convertible bonds Pre-financed vouchers (PFW) Obligations Hexagon Obligations Hexagon Contact for Investors Contact EN FR EN FR A pioneering biotechnology company focused on developing transformative therapies that impa … ducts. Read more BIOPHYTIS CHANGES ITS FINANCING AGREEMENT WITH HEXAGON CAPITAL FUND TO ENSURE ITS €2 MILLION FACILITY IS RENEWABLE May 28, 2026 Biophytis provides an update on the modification of the terms of the straight bond financing facility established with Hexagon Capital Fund (“Hexagon”) on August 5, 2025, amended for the first time on February 26, 2026, and amended a second time on May 22, 2026. These changes are part of Biophytis’… Read more BIOPHYTIS-LYNXKIT
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/ebook -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=100 -dGrayImageResolution=100 -dMonoImageResolution=100 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x�l�[�,=���~F�-�/�Ћ�C�~��-������e�@�����������O~%�/�������s������?�h � "���4�V��L˝g�s��y��Sp
EX-10.6 8 a2242774zex-10_6.htm EX-10.6 Exhibit 10.6 PORTIONS OF THIS EXHIBIT IDENTIFIED BY [*****] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Ref. SU C15/1731A01 Ref. SATT LUTECH: LIC3-2015-0011-AV01 (ST00022) AMENDMENT No. 1 TO THE LICENSE AGREEMENT Between : ·                       The company BIOPHYTIS , a public limited company w … Agreement is deleted and replaced as follows: “1.5 SCOPE, means any application associated with obesity (including in particular sarcopenic obesity), sarcopenia, diabetes, muscular dystrophy and in particular genetic muscular dystrophy (including the duchenne myopathy), cachexia (including cachexia linked to heart failure), neuromuscular diseases (including in particular spinal amyotrophy and amyotrophic lateral sclerosis), respiratory diseases (including in parti … uct, the level of competition of the market concerned in general or for a given application or indication, the changes in strategy, in particular clinical or regulatory changes, justified by the feedback from a regulatory authority, likely to affect the development or marketing of the PRODUCT or by compliance with the standards of the industry concerned by the PRODUCT (e.g. certification, approval...), likely to affect the development or marketing of the 3 PRODU … bsp; Declaration of invention (SATT LUTECH ref.) Priority application filing No. Priority application filing date Priority application title Co-owners PATENT 1 X07059 SL00419 FR0759478 30/11/2007 Utilisation of phytoecdysones in the preparation of a compound to act on metabolic syndrome BIOPHYTIS UPMC CNRS &nbs
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x��Y[o�D �onE5$mh%?��n�ug�s�Цi����]h���A��� ��Ǚ��9gl�}AB�Zi��9s.߹�{Y�R "�0�^ūJ�R�~N���h�ϛ��Y
M2 Pharma - Policy and Regulations You are required to be logged in to access the full website User Name: Password: Click here if you have forgotten your username or password Home Latest News Search About M2 Pharma Subscribe Business & Finance Generics Therapy Areas Policy & Regulation Research & Development People Policy & Regulation Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme 28 January 2026 - Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Wednesday that it has signed a st … e for antibody library technology Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe Copyright © 2026
BIOPHYTIS filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Biophytis files for FDA authorisation for first Phase III sarcopenia study Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories P … sessed, including walking speed, handgrip strength and quality of life. The FDA application comes shortly after submission to the European Medicines Agency (EMA) and Biophytis expects a response during Q3 2023. Biophytis CEO and chairman Stanislas Veillet commented: “Following the success of SARA-INT’s Phase IIb clinical trial, the filing of an application with the EMA in mid-May and with the FDA today for the launch of a Phase III clinical trial in sarcopenia is a majo
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket Download About Us Support العربية Invest Products Pricing Academy Free Stocks Hot Trading Sahm ID My Account Log Out Sign up / Log in Open Account Open Account Home News Detail Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket Benzinga News 09/04/2024 13:05 العربية Like Facebook Twitter Email Link Share Facebook Twitter Email Link Cancel Addex Therapeutics Ltd Sponsored ADR Anghami Inc. Brainstorm Cell Therapeutics Inc. Biophytis SA ADR BioSig Technologies Addex T